Since day one, BrainTale has been partnering with top academic centers, tier-one researchers, and leading biopharma companies to improve brain care by implementing precision neurology. The company measures the brain through white matter quantification and standardization with a commercially available software medical device solution.

With a collaborative approach, we enable drug developers, leading academic researchers, and key opinion leaders to improve patient care by understanding neuroinflammatory and neurodegenerative conditions, assess brain lesions evolutions and make appropriate decisions in the clinic and during drug development.

In practice, BrainTale’s software solution offers quality controlled, non-invasive, reliable and clinically validated reports after diffusion tensor MRI data processing. It is available with any MRI scanner, everywhere. With its regulatory-cleared AI solution, BrainTale empowers the scientific and medical community with objective measure to transform brain care.

Because brain diseases have become the medical issue of our time, we can no longer wait. At BrainTale, we strongly believe that by exploring better, we can treat faster, together.